- Home
- OPHC vs ATNM Comparison
OPHC vs ATNM Comparison
Compare OPHC & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPHC
- ATNM
- Stock Information
- Founded
- OPHC 2000
- ATNM 2000
- Country
- OPHC United States
- ATNM United States
- Employees
- OPHC N/A
- ATNM N/A
- Industry
- OPHC Major Banks
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- OPHC Finance
- ATNM Health Care
- Exchange
- OPHC Nasdaq
- ATNM Nasdaq
- Market Cap
- OPHC 49.0M
- ATNM 56.5M
- IPO Year
- OPHC N/A
- ATNM N/A
- Fundamental
- Price
- OPHC $4.94
- ATNM $1.24
- Analyst Decision
- OPHC Hold
- ATNM Strong Buy
- Analyst Count
- OPHC 1
- ATNM 5
- Target Price
- OPHC $5.25
- ATNM $10.20
- AVG Volume (30 Days)
- OPHC 80.4K
- ATNM 319.6K
- Earning Date
- OPHC 11-08-2024
- ATNM 11-14-2024
- Dividend Yield
- OPHC N/A
- ATNM N/A
- EPS Growth
- OPHC 78.77
- ATNM N/A
- EPS
- OPHC 1.32
- ATNM N/A
- Revenue
- OPHC $34,509,000.00
- ATNM $81,000.00
- Revenue This Year
- OPHC N/A
- ATNM $186.10
- Revenue Next Year
- OPHC N/A
- ATNM $19,248.94
- P/E Ratio
- OPHC $3.64
- ATNM N/A
- Revenue Growth
- OPHC 66.69
- ATNM N/A
- 52 Week Low
- OPHC $3.74
- ATNM $1.16
- 52 Week High
- OPHC $5.90
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- OPHC 53.11
- ATNM 35.90
- Support Level
- OPHC $4.84
- ATNM $1.16
- Resistance Level
- OPHC $5.04
- ATNM $1.29
- Average True Range (ATR)
- OPHC 0.11
- ATNM 0.09
- MACD
- OPHC -0.01
- ATNM 0.00
- Stochastic Oscillator
- OPHC 60.47
- ATNM 21.54
About OPHC OptimumBank Holdings Inc.
OptimumBank Holdings Inc serves as a bank holding company for OptimumBank. The Bank provides a range of community banking services to individuals and corporate customers. Its services include demand interest-bearing and non-interest-bearing accounts, negotiable order of withdrawal account, money market deposit accounts, debit cards, and automated teller machines.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.